3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Retinoblastoma
1
Interventions
Pemetrexed
4
Cisplatin
4
pembrolizumab
3
Drug Therapy
2
Carboplatin
2
toripalimab
1
tislelizumab
1
spartalizumab
1
sintilimab
1
penpulimab
1
nintedanib
1
camrelizumab
1
balstilimab
1
atezolizumab
1
anlotinib
1
Vincristine
1
Topotecan
1
Sentinel Lymph Node Biopsy
1
Platinum Compounds
1
Melphalan
1
Inosine
1
Injections
1
Indocyanine Green
1
Immunotherapy
1
Hyperthermia, Induced
1
Etoposide
1
Cryotherapy
1
Bevacizumab
1
ADI PEG20
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Hyperthermia, Induced
×
Other solid neoplasm
×
Clear all
NCT04681417
2025-11-28
RETINO 2018
Institut Curie
Phase 2/3
Recruiting
225 enrolled